2nd Quarter - Amendment — COHERUS BIOSCIENCES for COHERUS BIOSCIENCES, INC. (2024)

Firm

COHERUS BIOSCIENCES

Client

COHERUS BIOSCIENCES, INC.

Income

—

Expenses

$87,500

Expense method

A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing	Filed	Amount	Counted
2nd Quarter - Report	Jun 26, 2024	$30,000	Replaced
2nd Quarter - Amendment (this page)	Sep 26, 2024	$87,500	Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Domestic Manufacturing Medicare implications on biosimilars, Part D reform Drug Rebate Reform Appropriations pertaining to American Made preference HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 FDA foreign inspections ASPR/BARDA funding and policy Interchangeability of biosimilars legislation

Lobbyist	Covered position, as disclosed
BEN KENNEY	Director of Strategic Communications and External Affairs, Centers for Medicare and Medicaid Services (2018-2021), Associate Administrator, General Services Administration (2017-2018), Legislative Aide, U.S. Sen. Daniel R. Coats (2011-2012)
DAVID SANDERS	Legislative Affairs, Dept of Commerce, US Patent and Trademark Office (2005-2007) Legislative Assistant, Representative Marsha Blackburn (2002-2004) Legislative and Press Intern, Senator Fred Thompson (2000)

Contacted: HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); White House Office; Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); SENATE; Natl Security Council (NSC); Office of Science & Technology Policy (OSTP); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Defense, Dept of (DOD)

Bills named: S. 3311 (118th), S. 2082 (118th)

Government Issues GOV

Implementation of Buy American and Supply Chain Executive Orders American-Made Policies American-Made Supply Chain Security of the American Pharmaceutical and Medical Supply Chain Biosimilars Policy BARDA funding ASPR funding ARPA-H funding and implementation Industrial Supply and Financing IRA implementation Part D biosimilars utilization

Lobbyist	Covered position, as disclosed
BEN KENNEY	CMS, HHS
DAVID SANDERS	—

Contacted: Executive Office of the President (EOP); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); White House Office

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.